Guidelines

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients with Nonfunctioning Pituitary Adenomas

Maria Fleseriu, Mary E. Bodach, Luis M. Tumialan, Vivien Bonert, Nelson M. Oyesiku, Chirag G. Patil, Zachary Litvack, Manish K. Aghi, Gabriel Zada

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

BACKGROUND: Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. OBJECTIVE: To review the existing literature as it pertains to preoperative endocrine assessment in the workup for NFPAs. METHODS: A systematic review methodology was utilized to identify and screen articles assessing the role and results of preoperative laboratory assessment in patients with NFPAs. The prevalence of individual pituitary hormonal axis deficiencies was reviewed. RESULTS: Twenty-nine studies met inclusion criteria for analysis. No class I evidence was available, and all studies met criteria for class II evidence. Baseline serum laboratory assessment showed a prevalence of overall hypopituitarism in 37% to 85% of patients. The most common hormonal axis deficiency was growth hormone deficiency, prevalent in 61% to 100% of patients. The next most common deficit was hypogonadism, seen in 36% to 95% of patients. Adrenal insufficiency was diagnosed in 17% to 62% of patients. Finally, hypothyroidism was seen in 8% to 81% of patients. Hyperprolactinemia was seen in 25% to 65% of patients, with a mean level of 39 ng/mL and with a minority of patients exceeding a serum prolactin level of 200 ng/mL. No evidence supporting routine biomarker testing (eg, α-subunit or chromogranin A) or genetic testing in patients with sporadic NFPAs was available. CONCLUSION: Despite a paucity of class I evidence, multiple retrospective studies have demonstrated a high prevalence of hypopituitarism in patients with NFPAs. Routine endocrine analysis of all anterior pituitary axes to assess for hypopituitarism is recommended, with prolactin and insulin-like growth factor 1 evaluation also valuable to assess for hypersecretion states that might not be clinically suspected. The full guidelines document for this chapter can be located at https://www.cns.org/guidelines/guidelines-management-patients-non-functioning-pituitary-adenomas/Chapter-3.

Original languageEnglish (US)
Pages (from-to)E527-E529
JournalNeurosurgery
Volume79
Issue number4
DOIs
StatePublished - Oct 1 2016

Fingerprint

Pituitary Neoplasms
Guidelines
Hypopituitarism
Hyperprolactinemia
Prolactin
Chromogranin A
Adrenal Insufficiency
Hypogonadism
Genetic Testing
Somatomedins
Hypothyroidism
Serum
Growth Hormone
Retrospective Studies
Biomarkers

Keywords

  • Endocrine
  • Hormonal
  • Nonfunctioning pituitary adenoma
  • Preoperative

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Guidelines : Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients with Nonfunctioning Pituitary Adenomas. / Fleseriu, Maria; Bodach, Mary E.; Tumialan, Luis M.; Bonert, Vivien; Oyesiku, Nelson M.; Patil, Chirag G.; Litvack, Zachary; Aghi, Manish K.; Zada, Gabriel.

In: Neurosurgery, Vol. 79, No. 4, 01.10.2016, p. E527-E529.

Research output: Contribution to journalReview article

Fleseriu, Maria ; Bodach, Mary E. ; Tumialan, Luis M. ; Bonert, Vivien ; Oyesiku, Nelson M. ; Patil, Chirag G. ; Litvack, Zachary ; Aghi, Manish K. ; Zada, Gabriel. / Guidelines : Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients with Nonfunctioning Pituitary Adenomas. In: Neurosurgery. 2016 ; Vol. 79, No. 4. pp. E527-E529.
@article{737bdb3b6dbf4d2e8b8ee6ef5d52195a,
title = "Guidelines: Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients with Nonfunctioning Pituitary Adenomas",
abstract = "BACKGROUND: Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. OBJECTIVE: To review the existing literature as it pertains to preoperative endocrine assessment in the workup for NFPAs. METHODS: A systematic review methodology was utilized to identify and screen articles assessing the role and results of preoperative laboratory assessment in patients with NFPAs. The prevalence of individual pituitary hormonal axis deficiencies was reviewed. RESULTS: Twenty-nine studies met inclusion criteria for analysis. No class I evidence was available, and all studies met criteria for class II evidence. Baseline serum laboratory assessment showed a prevalence of overall hypopituitarism in 37{\%} to 85{\%} of patients. The most common hormonal axis deficiency was growth hormone deficiency, prevalent in 61{\%} to 100{\%} of patients. The next most common deficit was hypogonadism, seen in 36{\%} to 95{\%} of patients. Adrenal insufficiency was diagnosed in 17{\%} to 62{\%} of patients. Finally, hypothyroidism was seen in 8{\%} to 81{\%} of patients. Hyperprolactinemia was seen in 25{\%} to 65{\%} of patients, with a mean level of 39 ng/mL and with a minority of patients exceeding a serum prolactin level of 200 ng/mL. No evidence supporting routine biomarker testing (eg, α-subunit or chromogranin A) or genetic testing in patients with sporadic NFPAs was available. CONCLUSION: Despite a paucity of class I evidence, multiple retrospective studies have demonstrated a high prevalence of hypopituitarism in patients with NFPAs. Routine endocrine analysis of all anterior pituitary axes to assess for hypopituitarism is recommended, with prolactin and insulin-like growth factor 1 evaluation also valuable to assess for hypersecretion states that might not be clinically suspected. The full guidelines document for this chapter can be located at https://www.cns.org/guidelines/guidelines-management-patients-non-functioning-pituitary-adenomas/Chapter-3.",
keywords = "Endocrine, Hormonal, Nonfunctioning pituitary adenoma, Preoperative",
author = "Maria Fleseriu and Bodach, {Mary E.} and Tumialan, {Luis M.} and Vivien Bonert and Oyesiku, {Nelson M.} and Patil, {Chirag G.} and Zachary Litvack and Aghi, {Manish K.} and Gabriel Zada",
year = "2016",
month = "10",
day = "1",
doi = "10.1227/NEU.0000000000001387",
language = "English (US)",
volume = "79",
pages = "E527--E529",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Guidelines

T2 - Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline for Pretreatment Endocrine Evaluation of Patients with Nonfunctioning Pituitary Adenomas

AU - Fleseriu, Maria

AU - Bodach, Mary E.

AU - Tumialan, Luis M.

AU - Bonert, Vivien

AU - Oyesiku, Nelson M.

AU - Patil, Chirag G.

AU - Litvack, Zachary

AU - Aghi, Manish K.

AU - Zada, Gabriel

PY - 2016/10/1

Y1 - 2016/10/1

N2 - BACKGROUND: Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. OBJECTIVE: To review the existing literature as it pertains to preoperative endocrine assessment in the workup for NFPAs. METHODS: A systematic review methodology was utilized to identify and screen articles assessing the role and results of preoperative laboratory assessment in patients with NFPAs. The prevalence of individual pituitary hormonal axis deficiencies was reviewed. RESULTS: Twenty-nine studies met inclusion criteria for analysis. No class I evidence was available, and all studies met criteria for class II evidence. Baseline serum laboratory assessment showed a prevalence of overall hypopituitarism in 37% to 85% of patients. The most common hormonal axis deficiency was growth hormone deficiency, prevalent in 61% to 100% of patients. The next most common deficit was hypogonadism, seen in 36% to 95% of patients. Adrenal insufficiency was diagnosed in 17% to 62% of patients. Finally, hypothyroidism was seen in 8% to 81% of patients. Hyperprolactinemia was seen in 25% to 65% of patients, with a mean level of 39 ng/mL and with a minority of patients exceeding a serum prolactin level of 200 ng/mL. No evidence supporting routine biomarker testing (eg, α-subunit or chromogranin A) or genetic testing in patients with sporadic NFPAs was available. CONCLUSION: Despite a paucity of class I evidence, multiple retrospective studies have demonstrated a high prevalence of hypopituitarism in patients with NFPAs. Routine endocrine analysis of all anterior pituitary axes to assess for hypopituitarism is recommended, with prolactin and insulin-like growth factor 1 evaluation also valuable to assess for hypersecretion states that might not be clinically suspected. The full guidelines document for this chapter can be located at https://www.cns.org/guidelines/guidelines-management-patients-non-functioning-pituitary-adenomas/Chapter-3.

AB - BACKGROUND: Nonfunctioning pituitary adenomas (NFPAs) are among the most common pituitary lesions and may present with hypopituitarism and/or hyperprolactinemia. OBJECTIVE: To review the existing literature as it pertains to preoperative endocrine assessment in the workup for NFPAs. METHODS: A systematic review methodology was utilized to identify and screen articles assessing the role and results of preoperative laboratory assessment in patients with NFPAs. The prevalence of individual pituitary hormonal axis deficiencies was reviewed. RESULTS: Twenty-nine studies met inclusion criteria for analysis. No class I evidence was available, and all studies met criteria for class II evidence. Baseline serum laboratory assessment showed a prevalence of overall hypopituitarism in 37% to 85% of patients. The most common hormonal axis deficiency was growth hormone deficiency, prevalent in 61% to 100% of patients. The next most common deficit was hypogonadism, seen in 36% to 95% of patients. Adrenal insufficiency was diagnosed in 17% to 62% of patients. Finally, hypothyroidism was seen in 8% to 81% of patients. Hyperprolactinemia was seen in 25% to 65% of patients, with a mean level of 39 ng/mL and with a minority of patients exceeding a serum prolactin level of 200 ng/mL. No evidence supporting routine biomarker testing (eg, α-subunit or chromogranin A) or genetic testing in patients with sporadic NFPAs was available. CONCLUSION: Despite a paucity of class I evidence, multiple retrospective studies have demonstrated a high prevalence of hypopituitarism in patients with NFPAs. Routine endocrine analysis of all anterior pituitary axes to assess for hypopituitarism is recommended, with prolactin and insulin-like growth factor 1 evaluation also valuable to assess for hypersecretion states that might not be clinically suspected. The full guidelines document for this chapter can be located at https://www.cns.org/guidelines/guidelines-management-patients-non-functioning-pituitary-adenomas/Chapter-3.

KW - Endocrine

KW - Hormonal

KW - Nonfunctioning pituitary adenoma

KW - Preoperative

UR - http://www.scopus.com/inward/record.url?scp=84988411334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988411334&partnerID=8YFLogxK

U2 - 10.1227/NEU.0000000000001387

DO - 10.1227/NEU.0000000000001387

M3 - Review article

VL - 79

SP - E527-E529

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -